Comparison of the effect of mutant and wild-type p53 on global gene expression

被引:42
作者
O'Farrell, TJ [1 ]
Ghosh, P [1 ]
Dobashi, N [1 ]
Sasaki, CY [1 ]
Longo, DL [1 ]
机构
[1] NIA, Gerontol Res Ctr, Lab Immunol, NIH, Baltimore, MD 21224 USA
关键词
D O I
10.1158/0008-5472.CAN-03-3639
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mechanisms for "gain-of-function" phenotypes produced by mutant p53s such as enhanced proliferation, resistance to transforming growth factor-beta-mediated growth suppression, and increased tumorigenesis are not known. One theory is that these phenotypes are caused by novel transcriptional regulatory events acquired by mutant p53s. Another explanation is that these effects are a result of an imbalance of functions caused by the retention of some of the wild-type transcriptional regulatory events in the context of a loss of other counterbalancing activities. An analysis of the ability of DNA-binding domain mutants A138P and R175H, and wild-type, p53 to regulate the expression levels of 6.9 x 10(3) genes revealed that the mutants retained only <5% of the regulatory activities of the wild-type protein. A138P p53 exhibited mostly retained wild-type regulatory activities and few acquired novel events. However, R175H p53 possessed an approximately equal number of wild-type regulatory events and novel activities. This is the first report that, after examination of the regulation of a large unfocused set of genes, provides data indicating that remaining wild-type transcriptional regulatory functions existing in the absence of counterbalancing activities as well as acquired novel events both contribute to the gain-of-function phenotypes produced by mutant p53s. However, mutant p53s are likely to be distinct in terms of the extent to which each mechanism contributes to their gain-of-function phenotypes.
引用
收藏
页码:8199 / 8207
页数:9
相关论文
共 64 条
[1]   ANTI-IGM INDUCES TRANSFORMING GROWTH-FACTOR-BETA SENSITIVITY IN A HUMAN B-LYMPHOMA CELL-LINE - INHIBITION OF GROWTH IS ASSOCIATED WITH A DOWN-REGULATION OF MUTANT P53 [J].
BECKWITH, M ;
RUSCETTI, FW ;
SING, GK ;
URBA, WJ ;
LONGO, DL .
BLOOD, 1995, 85 (09) :2461-2470
[2]   p53 gene mutation:: software and database [J].
Béroud, C ;
Soussi, T .
NUCLEIC ACIDS RESEARCH, 1998, 26 (01) :200-204
[3]   p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect [J].
Blagosklonny, MV .
FASEB JOURNAL, 2000, 14 (13) :1901-1907
[4]   Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy [J].
Blandino, G ;
Levine, AJ ;
Oren, M .
ONCOGENE, 1999, 18 (02) :477-485
[5]   Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy [J].
Bullock, AN ;
Henckel, J ;
Fersht, AR .
ONCOGENE, 2000, 19 (10) :1245-1256
[6]   p53 is a general repressor of RNA polymerase III transcription [J].
Cairns, CA ;
White, RJ .
EMBO JOURNAL, 1998, 17 (11) :3112-3123
[7]   p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements [J].
Campomenosi, P ;
Monti, P ;
Aprile, A ;
Abbondandolo, A ;
Frebourg, T ;
Gold, B ;
Crook, T ;
Inga, A ;
Resnick, MA ;
Iggo, R ;
Fronza, G .
ONCOGENE, 2001, 20 (27) :3573-3579
[8]  
Cardinali M, 1997, MOL CARCINOGEN, V18, P78, DOI 10.1002/(SICI)1098-2744(199702)18:2<78::AID-MC3>3.0.CO
[9]  
2-M
[10]   HOT-SPOT P53 MUTANTS INTERACT SPECIFICALLY WITH 2 CELLULAR PROTEINS DURING PROGRESSION OF THE CELL-CYCLE [J].
CHEN, YM ;
CHEN, PL ;
LEE, WH .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (10) :6764-6772